These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 17920762)

  • 1. In vitro and in vivo antitumor effects of doxorubicin loaded with bacterial magnetosomes (DBMs) on H22 cells: the magnetic bio-nanoparticles as drug carriers.
    Sun JB; Duan JH; Dai SL; Ren J; Zhang YD; Tian JS; Li Y
    Cancer Lett; 2007 Dec; 258(1):109-17. PubMed ID: 17920762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and anti-tumor efficiency evaluation of doxorubicin-loaded bacterial magnetosomes: magnetic nanoparticles as drug carriers isolated from Magnetospirillum gryphiswaldense.
    Sun JB; Duan JH; Dai SL; Ren J; Guo L; Jiang W; Li Y
    Biotechnol Bioeng; 2008 Dec; 101(6):1313-20. PubMed ID: 18980188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preparation of doxorubicin encapsulated in amphiphilic polysaccharide nanoparticles and anti-hepatocarcinoma effect thereof].
    Huang YF; Gu WL; Li ZH; Chen RF; Zhou JJ; Zhou QB; Guo N
    Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(12):810-2. PubMed ID: 19595118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
    Wong HL; Rauth AM; Bendayan R; Wu XY
    Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
    Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
    J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
    Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
    Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer.
    Liang G; Tang A; Lin X; Li L; Zhang S; Huang Z; Tang H; Li QQ
    Int J Oncol; 2010 Jul; 37(1):111-23. PubMed ID: 20514403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
    Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H
    Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
    Yoshimoto Y; Kawada M; Ikeda D; Ishizuka M
    Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer.
    Maeng JH; Lee DH; Jung KH; Bae YH; Park IS; Jeong S; Jeon YS; Shim CK; Kim W; Kim J; Lee J; Lee YM; Kim JH; Kim WH; Hong SS
    Biomaterials; 2010 Jun; 31(18):4995-5006. PubMed ID: 20347138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterial magnetosomes loaded with doxorubicin and transferrin improve targeted therapy of hepatocellular carcinoma.
    Wang J; Geng Y; Zhang Y; Wang X; Liu J; Basit A; Miao T; Liu W; Jiang W
    Nanotheranostics; 2019; 3(3):284-298. PubMed ID: 31423412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
    Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
    Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thermoresponsive core-shell magnetic nanoparticles for combined modalities of cancer therapy.
    Purushotham S; Chang PE; Rumpel H; Kee IH; Ng RT; Chow PK; Tan CK; Ramanujan RV
    Nanotechnology; 2009 Jul; 20(30):305101. PubMed ID: 19581698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles.
    Azarmi S; Tao X; Chen H; Wang Z; Finlay WH; Löbenberg R; Roa WH
    Int J Pharm; 2006 Aug; 319(1-2):155-61. PubMed ID: 16713150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug.
    Jain A; Agarwal A; Majumder S; Lariya N; Khaya A; Agrawal H; Majumdar S; Agrawal GP
    J Control Release; 2010 Dec; 148(3):359-67. PubMed ID: 20854859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of metastatic carcinoma cell growth in livers by poly(I):poly(C)/cationic liposome complex (LIC).
    Hirabayashi K; Yano J; Takesue H; Fujiwara N; Irimura T
    Oncol Res; 1999; 11(11-12):497-504. PubMed ID: 10905561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo antitumor activity of doxorubicin-loaded alginic-acid-based nanoparticles.
    Cheng Y; Yu S; Wang J; Qian H; Wu W; Jiang X
    Macromol Biosci; 2012 Oct; 12(10):1326-35. PubMed ID: 22887841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel method of doxorubicin-SPION reversible association for magnetic drug targeting.
    Munnier E; Cohen-Jonathan S; Linassier C; Douziech-Eyrolles L; Marchais H; Soucé M; Hervé K; Dubois P; Chourpa I
    Int J Pharm; 2008 Nov; 363(1-2):170-6. PubMed ID: 18687392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
    Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
    Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity.
    Park K; Lee GY; Kim YS; Yu M; Park RW; Kim IS; Kim SY; Byun Y
    J Control Release; 2006 Sep; 114(3):300-6. PubMed ID: 16884806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.